4d Pharma PLC Director/PDMR Shareholding (9117Z)

TIDMDDDD

RNS Number : 9117Z

4d Pharma PLC

23 May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that Duncan Peyton (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

 
 Name                      Shares in   % of total     Shares in   % of total 
                           4D pharma    shares in     4D pharma    shares in 
                          plc before        issue     plc after        issue 
                            purchase                   purchase 
 
 Duncan Peyton (CEO)       6,445,184        9.84%     6,455,075        9.86% 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1      Details of the person discharging managerial responsibilities 
         / person closely associated 
 a)     Name                         Duncan Peyton 
       ---------------------------  ------------------------------------- 
 2      Reason for the notification 
       ------------------------------------------------------------------ 
 a)     Position/status              PDMR 
       ---------------------------  ------------------------------------- 
 b)     Initial notification         Initial notification 
         /Amendment 
       ---------------------------  ------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ------------------------------------------------------------------ 
 a)     Name                         4D Pharma plc 
       ---------------------------  ------------------------------------- 
 b)     LEI                          213800O49VYSXWE2ZD52 
       ---------------------------  ------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
       ------------------------------------------------------------------ 
 a)     Description of the           Ordinary shares of GBP0.0025 
         financial instrument,        ISIN: GB00BJL5BR07 
         type of instrument 
         Identification code 
       ---------------------------  ------------------------------------- 
 b)     Nature of the transaction    Purchase of Ordinary Shares 
       ---------------------------  ------------------------------------- 
 c)     Price(s) and volume(s)         Price(s)   Volume(s) 
                                        105p       9,891 
                                                  ---------- 
       ---------------------------  ------------------------------------- 
 d)     Aggregated information 
         - Aggregated volume           N/A 
         - Price 
       ---------------------------  ------------------------------------- 
 e)     Date of the transaction      22(nd) May 2019 
       ---------------------------  ------------------------------------- 
 f)     Place of the transaction     London Stock Exchange, AIM 
       ---------------------------  ------------------------------------- 
 
 
 
 

For further information please contact:

 
4D 
Duncan Peyton, Chief Executive Officer         + 44 (0)113 895 0130 
 Fay Weston, Head of Investor Relations         + 44 (0)7990 381713 
Zeus Capital Limited - Nomad and Joint Broker  [phone] 
Dan Bate / Jordan Warburton 
Bryan Garnier & Co. Limited - Joint Broker     [phone] 
Dominic Wilson 
 Phil Walker 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAKSAASPNEFF

(END) Dow Jones Newswires

May 23, 2019 02:01 ET (06:01 GMT)